| Filed On | Filing |
|---|---|
| 23 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Material Modifications to Rights of Security Holders
This Amendment No. 1, dated as of October 23, 2026 (this “Amendment”), amends that certain Rights Agreement, dated as of October 27, 2025 (the “Rights Agreement”), by and between Neuphoria Therapeutics Inc., a Delaware corporation (the “... |
| 05 Oct 2026 | SCHEDULE 13G |
| 18 Sep 2026 | DEFA14A |
| 18 Sep 2026 | DEFA14A |
| 18 Sep 2026 | Proxy statement: annual meeting on November 2, 2026 |
| 18 Sep 2026 | 10-K |
| 28 Jul 2026 | SCHEDULE 13G/A |
| 24 Jul 2026 | CURRENT REPORT |
| 24 Jul 2026 | 8-K: Entry into a Material Definitive Agreement; Changes in Control of Registrant +1 more |
| 26 May 2026 | 8-K: Other Events |
| 15 May 2026 | 10-Q |
| 17 Feb 2026 | 10-Q |
| 06 Feb 2026 | SCHEDULE 13G/A |
| 21 Jan 2026 |
Form 4: Wilson David Ian, Director
Granted 8,537 Restricted Stock Units |
| 21 Jan 2026 |
Form 4: Davies Peter Miles Winston, Director
Granted 8,537 Restricted Stock Units |
| 21 Jan 2026 |
Form 4: Fisher Alan, Director
Granted 17,073 Restricted Stock Units |
| 21 Jan 2026 |
Form 4: Ryan Jane, Director
Granted 8,537 Restricted Stock Units |
| 08 Jan 2026 | 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement |
| 29 Dec 2025 | SCHEDULE 13D/A |
| 18 Dec 2025 | 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule |
Loading...
